Bullous systemic lupus erythematosus: Response to dapsone in two patients

Sirka, C S; Padhi, Tanmay; Mohanty, Pranita; Patel, Dilip Kumar; Parida, P R; Kar, Chinmaya

doi:10.4103/0378-6323.13795

Cited by 19 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It appears that the close relationship between bullous SLE and lupus nephritis is also important in children, as demonstrated by Sirka et al [11], Vijayalakshmi and Jayavardhana [12], Kumar and Agarwal [13], and the first of the two cases presented here.…”

Section: Discussionsupporting

confidence: 78%

“…Bullous SLE is a rare, transient autoimmune bullous disease that occurs in established cases of SLE [11]. It appears in less than 5% of patients with SLE, either in isolation or in addition to other cutaneous manifestations [15].…”

Section: Discussionmentioning

confidence: 99%

“…Epidermolysis bullosa acquisita (EBA) is histopathologically and immunopathologically identical since both are mediated by circulating antibodies against type VII collagen. However, a dramatic therapeutic response to dapsone in bullous SLE differentiates it from EBA [11]. When in a linear disposition, herpes zoster can be considered in the differential, but it can be easily differentiated by histopathology [6].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Bullous lesions as a manifestation of systemic lupus erythematosus in two Mexican teenagers

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bullous lesions as a manifestation of systemic lupus erythematosus in two Mexican teenagers

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Interestingly, improvement of the eruption did not correlate with amelioration of the systemic manifestations [ 25 ]. The dramatic response to dapsone therapy demonstrated that dapsone is useful in treating bullous lesions of SLE [ 5 , 15 , 16 , 26 ]. Notably, the blistering eruption was not improved by dapsone in some cases, and even worsening has been noted after its administration.…”

Section: Literature Reviewmentioning

confidence: 99%

Treatment of Bullous Systemic Lupus Erythematosus

Duan

Chen

Zhong

et al. 2015

Journal of Immunology Research

View full text Add to dashboard Cite

Bullous systemic lupus erythematosus (BSLE) is an autoantibody-mediated vesiculobullous disease in patients with SLE. Autoimmunity in BSLE is characterized by the presence of circulating anti-type VII collagen antibodies. BSLE patients often present with multiple, tense, clear fluid-filled vesicles and bullae overlying erythematous edematous plaques. Skin biopsy from BSLE patients shows subepidermal bullae with numerous neutrophils and only occasional eosinophils. Furthermore, immunofluorescence examination showed linear deposition of lgG, lgA, C3, and C1q along the basement membrane zone. BSLE patients with corticosteroids treatment constantly do not receive a marked improvement, while dapsone generally dramatically improved the skin condition. Recently, it has been reported that quite a few cases of BSLE were successfully treated with other immune suppressive drugs. Therefore, a comprehensive review of the treatment of BSLE would be beneficial to cure the disease.

show abstract

“…In conclusion, although BSLE is rare, it should be considered in the differential diagnosis for young children presenting with an acute vesicobullous eruption, especially those without a previous diagnosis of SLE. Given the potential association between BSLE and lupus nephritis, physicians should have a low threshold of suspicion to obtain a diagnostic skin biopsy to expedite proper treatment and avert SLE‐associated complications …”

Section: Discussionmentioning

confidence: 99%